{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:07:24Z","timestamp":1793783244438,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04073-z","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:13:37Z","timestamp":1778120017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of botulinum toxin type a for treating chronic low back pain: a systematic review and metanalysis"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9887-2434","authenticated-orcid":false,"given":"Bharath Kumar","family":"G","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantu","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash Ranjan","family":"Meher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biswa Mohan","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Sakale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"2","key":"4073_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00007632-200001150-00018","volume":"25","author":"M Rossignol","year":"2000","unstructured":"Rossignol M, Abenhaim L, Seguin P, Neveu A, Collet JP, Ducruet T et al (2000) Coordination of primary health care for back pain. A randomized controlled trial. Spine (Phila Pa 1976) 25(2):251\u2013258","journal-title":"Spine (Phila Pa 1976)"},{"issue":"6","key":"4073_CR2","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/S2665-9913(23)00098-X","volume":"5","author":"Collaborators GBDLBP","year":"2023","unstructured":"Collaborators GBDLBP (2023) Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: A systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol 5(6):e316\u2013e329","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"4073_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.pain.2009.11.002","volume":"148","author":"NE Foster","year":"2010","unstructured":"Foster NE, Thomas E, Bishop A, Dunn KM, Main CJ (2010) Distinctiveness of psychological obstacles to recovery in low back pain patients in primary care. Pain 148(3):398\u2013406","journal-title":"Pain"},{"issue":"6","key":"4073_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/jama.2013.13805","volume":"310","author":"CJ Murray","year":"2013","unstructured":"Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D et al (2013) The state of US health, 1990\u20132010: burden of diseases, injuries, and risk factors. JAMA 310(6):591\u2013608","journal-title":"JAMA"},{"key":"4073_CR5","doi-asserted-by":"publisher","unstructured":"Farley T, Stokke J, Goyal K, DeMicco R. Chronic Low Back Pain: History, Symptoms, Pain Mechanisms, and Treatment. Life (Basel). 2024;14(7):812. https:\/\/doi.org\/10.3390\/life14070812","DOI":"10.3390\/life14070812"},{"issue":"7","key":"4073_CR6","doi-asserted-by":"publisher","first-page":"514","DOI":"10.7326\/M16-2367","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Wilt TJ, McLean RM, Forciea MA, Clinical Guidelines Committee of the American College of P, Denberg TD, Clinical Guidelines Committee of the American College of Physicians et al (2017) Noninvasive treatments for acute, subacute, and chronic low back pain: A clinical practice guideline from the American College of Physicians. Ann Intern Med 166(7):514\u2013530","journal-title":"Ann Intern Med"},{"key":"4073_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041685","author":"V Nicol","year":"2023","unstructured":"Nicol V, Verdaguer C, Daste C, Bisseriex H, Lapeyre E, Lefevre-Colau MM et al (2023) Chronic low back pain: A narrative review of recent international guidelines for diagnosis and conservative treatment. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12041685","journal-title":"J Clin Med"},{"key":"4073_CR8","unstructured":"World Health Organization. WHO guideline on the management of chronic primary low back pain in adults. Geneva: World Health Organization; 2023. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240081789"},{"issue":"1","key":"4073_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/0019-5154.60343","volume":"55","author":"PK Nigam","year":"2010","unstructured":"Nigam PK, Nigam A (2010) Botulinum toxin. Indian J Dermatol 55(1):8\u201314","journal-title":"Indian J Dermatol"},{"issue":"8","key":"4073_CR10","doi-asserted-by":"publisher","first-page":"e70187","DOI":"10.1111\/jnc.70187","volume":"169","author":"A Monash","year":"2025","unstructured":"Monash A, Tam J, Rosen O, Soreq H (2025) Botulinum Neurotoxins: history, mechanism, and applications. A narrative review. J Neurochem 169(8):e70187","journal-title":"J Neurochem"},{"issue":"1","key":"4073_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0304-3959(94)90048-5","volume":"59","author":"WP Cheshire","year":"1994","unstructured":"Cheshire WP, Abashian SW, Mann DJ (1994) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59(1):65\u201369","journal-title":"Pain"},{"issue":"1","key":"4073_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0039-6257(97)81995-9","volume":"41","author":"JJ Dutton","year":"1996","unstructured":"Dutton JJ (1996) Botulinum-A toxin in the treatment of craniocervical muscle spasms: short- and long-term, local and systemic effects. Surv Ophthalmol 41(1):51\u201365","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"4073_CR13","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1212\/WNL.45.4.712","volume":"45","author":"MA Grazko","year":"1995","unstructured":"Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin a for spasticity, muscle spasms, and rigidity. Neurology 45(4):712\u2013717","journal-title":"Neurology"},{"issue":"11","key":"4073_CR14","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/j.1526-4637.2011.01245.x","volume":"12","author":"B Jabbari","year":"2011","unstructured":"Jabbari B, Machado D (2011) Treatment of refractory pain with botulinum toxins--an evidence-based review. Pain Med 12(11):1594\u20131606","journal-title":"Pain Med"},{"issue":"1","key":"4073_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-017-0744-z","volume":"18","author":"G Sandrini","year":"2017","unstructured":"Sandrini G, De Icco R, Tassorelli C, Smania N, Tamburin S (2017) Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain 18(1):38","journal-title":"J Headache Pain"},{"issue":"4","key":"4073_CR16","doi-asserted-by":"publisher","first-page":"e4796","DOI":"10.1002\/ejp.4796","volume":"29","author":"W Wagrees","year":"2025","unstructured":"Wagrees W, Kelani H, Salamah HM, Mahmoud A, Khlidj Y, Abdelraouf MR et al (2025) The efficacy and safety of Botulinum Neurotoxin Type A in treating chronic low back pain: a systematic review, meta-analysis, trial sequential analysis, and meta-regression. Eur J Pain 29(4):e4796","journal-title":"Eur J Pain"},{"issue":"1","key":"4073_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4(1):1","journal-title":"Syst Rev"},{"issue":"3","key":"4073_CR18","doi-asserted-by":"publisher","first-page":"e1003583","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med 18(3):e1003583","journal-title":"PLoS Med"},{"key":"4073_CR19","unstructured":"Costa P, Hodges PW. Low back pain (fact sheet). International Association for the Study of Pain; 2023. Available from: https:\/\/www.iasp-pain.org\/resources\/fact-sheets\/low-back-pain\/"},{"key":"4073_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8120374","author":"D Machado","year":"2016","unstructured":"Machado D, Kumar A, Jabbari B (2016) Abobotulinum Toxin A in the treatment of chronic low back pain. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins8120374","journal-title":"Toxins (Basel)"},{"issue":"2","key":"4073_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5812\/aapm.1845","volume":"1","author":"SM Jazayeri","year":"2011","unstructured":"Jazayeri SM, Ashraf A, Fini HM, Karimian H, Nasab MV (2011) Efficacy of botulinum toxin type a for treating chronic low back pain. Anesth Pain Med 1(2):77\u201380","journal-title":"Anesth Pain Med"},{"issue":"10","key":"4073_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1212\/WNL.56.10.1290","volume":"56","author":"L Foster","year":"2001","unstructured":"Foster L, Clapp L, Erickson M, Jabbari B (2001) Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 56(10):1290\u20131293","journal-title":"Neurology"},{"issue":"3","key":"4073_CR23","doi-asserted-by":"publisher","first-page":"93854","DOI":"10.5662\/wjm.v14.i3.93854","volume":"14","author":"M Jain","year":"2024","unstructured":"Jain M, Khan S, Varghese P, Tripathy SK, Mangaraj M (2024) Botulinum toxin type A for treating chronic low back pain: A double blinded randomized control study. World J Methodol 14(3):93854","journal-title":"World J Methodol"},{"issue":"1","key":"4073_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12891-017-1816-6","volume":"18","author":"M Cogne","year":"2017","unstructured":"Cogne M, Petit H, Creuze A, Liguoro D, de Seze M (2017) Are paraspinous intramuscular injections of botulinum toxin a (BoNT-A) efficient in the treatment of chronic low-back pain? A randomised, double-blinded crossover trial. BMC Musculoskelet Disord 18(1):454","journal-title":"BMC Musculoskelet Disord"},{"issue":"5","key":"4073_CR25","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/ije\/dys124","volume":"41","author":"BR da Costa","year":"2012","unstructured":"da Costa BR, Rutjes AW, Johnston BC, Reichenbach S, Nuesch E, Tonia T et al (2012) Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. Int J Epidemiol 41(5):1445\u20131459","journal-title":"Int J Epidemiol"},{"key":"4073_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"4073_CR27","unstructured":"Cumpston M, Thomas J, Higgins JPT, Deeks JJ, Clarke MJ. Chapter 1: Introduction. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions, version 6.4 (updated August 2023). Chichester (UK): John Wiley & Sons; 2023. Available from: . . https:\/\/training.cochrane.org\/handbook. Accessed 30 April 2026"},{"issue":"7","key":"4073_CR28","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s10072-013-1357-1","volume":"34","author":"R Ravenni","year":"2013","unstructured":"Ravenni R, De Grandis D, Mazza A (2013) Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci 34(7):1043\u20131048","journal-title":"Neurol Sci"},{"key":"4073_CR29","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4. Copenhagen: The Nordic Cochrane Centre; 2020. Available from: https:\/\/training.cochrane.org\/software\/revman. Accessed 30 April 2026"},{"key":"4073_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36:1\u201348","journal-title":"J Stat Softw"},{"issue":"6","key":"4073_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2165","volume":"7","author":"SA Nejadghaderi","year":"2024","unstructured":"Nejadghaderi SA, Balibegloo M, Rezaei N (2024) The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons. Health Sci Rep 7(6):e2165","journal-title":"Health Sci Rep"},{"issue":"4","key":"4073_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4073_CR33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mehy.2006.06.033","volume":"68","author":"HM Langevin","year":"2007","unstructured":"Langevin HM, Sherman KJ (2007) Pathophysiological model for chronic low back pain integrating connective tissue and nervous system mechanisms. Med Hypotheses 68(1):74\u201380","journal-title":"Med Hypotheses"},{"key":"4073_CR34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2147\/JPR.S306280","volume":"14","author":"W Li","year":"2021","unstructured":"Li W, Gong Y, Liu J, Guo Y, Tang H, Qin S et al (2021) Peripheral and central pathological mechanisms of chronic low back pain: A narrative review. J Pain Res 14:1483\u20131494","journal-title":"J Pain Res"},{"key":"4073_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11080459","author":"I Matak","year":"2019","unstructured":"Matak I, Bolcskei K, Bach-Rojecky L, Helyes Z (2019) Mechanisms of Botulinum Toxin Type A action on pain. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins11080459","journal-title":"Toxins (Basel)"},{"key":"4073_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10050886","author":"M Adler","year":"2022","unstructured":"Adler M, Pellett S, Sharma SK, Lebeda FJ, Dembek ZF, Mahan MA (2022) Preclinical evidence for the role of Botulinum Neurotoxin A (BoNT\/A) in the treatment of peripheral nerve injury. Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms10050886","journal-title":"Microorganisms"},{"key":"4073_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuroscience.2017.07.011","volume":"359","author":"S Cobianchi","year":"2017","unstructured":"Cobianchi S, Jaramillo J, Luvisetto S, Pavone F, Navarro X (2017) Botulinum neurotoxin A promotes functional recovery after peripheral nerve injury by increasing regeneration of myelinated fibers. Neuroscience 359:82\u201391","journal-title":"Neuroscience"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04073-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04073-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:17:44Z","timestamp":1781072264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04073-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04073-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T\/IM-NF\/Ortho\/24\/59.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No participants were recruited specifically for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"There are no conflicts of interest.\n                      Clinical trial number\n                      Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"143"}}